Ascendis Pharma A/S (NASDAQ:ASND) Expected to Announce Quarterly Sales of $7.64 Million

Equities analysts expect that Ascendis Pharma A/S (NASDAQ:ASNDGet Rating) will report $7.64 million in sales for the current fiscal quarter, Zacks reports. Five analysts have provided estimates for Ascendis Pharma A/S’s earnings. The highest sales estimate is $10.07 million and the lowest is $4.10 million. Ascendis Pharma A/S reported sales of $1.23 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 521.1%. The company is scheduled to announce its next earnings report on Monday, January 1st.

On average, analysts expect that Ascendis Pharma A/S will report full-year sales of $40.60 million for the current financial year, with estimates ranging from $28.88 million to $49.04 million. For the next fiscal year, analysts expect that the firm will post sales of $141.15 million, with estimates ranging from $66.72 million to $222.35 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Ascendis Pharma A/S.

Ascendis Pharma A/S (NASDAQ:ASNDGet Rating) last released its earnings results on Wednesday, May 11th. The biotechnology company reported ($2.21) EPS for the quarter, beating the consensus estimate of ($2.25) by $0.04. Ascendis Pharma A/S had a negative return on equity of 54.58% and a negative net margin of 3,281.45%. During the same period last year, the company earned ($1.41) earnings per share.

Several equities analysts recently commented on ASND shares. Oppenheimer dropped their target price on Ascendis Pharma A/S from $166.00 to $154.00 in a research note on Thursday, May 12th. Credit Suisse Group dropped their price target on Ascendis Pharma A/S from $194.00 to $123.00 in a research note on Thursday, May 12th. Wells Fargo & Company dropped their price target on Ascendis Pharma A/S from $190.00 to $176.00 in a research note on Thursday, May 12th. Bank of America upgraded Ascendis Pharma A/S from a “neutral” rating to a “buy” rating and upped their price target for the stock from $148.00 to $161.00 in a research note on Tuesday, March 15th. Finally, Wedbush restated an “outperform” rating on shares of Ascendis Pharma A/S in a research note on Monday, March 28th. One analyst has rated the stock with a sell rating, two have issued a hold rating and ten have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Ascendis Pharma A/S currently has an average rating of “Buy” and a consensus price target of $160.64.

Ascendis Pharma A/S stock opened at $85.19 on Tuesday. The firm has a market capitalization of $4.85 billion, a P/E ratio of -9.10 and a beta of 0.87. The stock has a fifty day moving average price of $98.24 and a 200 day moving average price of $114.56. Ascendis Pharma A/S has a 52 week low of $61.58 and a 52 week high of $178.71. The company has a current ratio of 11.76, a quick ratio of 10.79 and a debt-to-equity ratio of 0.69.

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Atria Investments LLC boosted its holdings in Ascendis Pharma A/S by 0.9% in the fourth quarter. Atria Investments LLC now owns 9,576 shares of the biotechnology company’s stock valued at $1,288,000 after purchasing an additional 88 shares during the last quarter. OneAscent Financial Services LLC boosted its holdings in Ascendis Pharma A/S by 3.2% in the fourth quarter. OneAscent Financial Services LLC now owns 3,560 shares of the biotechnology company’s stock valued at $479,000 after purchasing an additional 109 shares during the last quarter. Profund Advisors LLC boosted its holdings in Ascendis Pharma A/S by 4.4% in the third quarter. Profund Advisors LLC now owns 3,124 shares of the biotechnology company’s stock valued at $498,000 after purchasing an additional 133 shares during the last quarter. Guggenheim Capital LLC boosted its holdings in Ascendis Pharma A/S by 7.2% in the first quarter. Guggenheim Capital LLC now owns 2,008 shares of the biotechnology company’s stock valued at $236,000 after purchasing an additional 135 shares during the last quarter. Finally, SG Americas Securities LLC boosted its holdings in Ascendis Pharma A/S by 17.8% in the first quarter. SG Americas Securities LLC now owns 942 shares of the biotechnology company’s stock valued at $111,000 after purchasing an additional 142 shares during the last quarter.

Ascendis Pharma A/S Company Profile (Get Rating)

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia.

See Also

Get a free copy of the Zacks research report on Ascendis Pharma A/S (ASND)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Ascendis Pharma A/S (NASDAQ:ASND)

Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.